# Cannabinoid Clinical Trials: Cannabis Use for Anxiety > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-use-for-anxiety-clinical-trials-effects/ > **Published:** 2026-03-10T17:14:22-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:09:30-04:00 > **Clinical Summary:** Explore cannabis use for anxiety with clinical trial insights on THC, CBD, flower, and edibles effects to guide safe and informed decisions. --- #### Clinical Takeaway Cannabis use for anxiety showed different daily and long-term effects depending on whether people used flower or edible products, and whether the product contained THC, CBD, or both. While CBD may support anxiety reduction, THC-dominant products carry the potential for variable or worsening anxiety outcomes, particularly with edibles where dosing is less predictable. Patients considering cannabis for anxiety should discuss product type, cannabinoid ratios, and delivery method with a knowledgeable clinician before use. ### #8 Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products. **Citation:** Rosa Luiza et al. *Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.* International journal of environmental research and public health. 2026. PMID: 41752306. **Study type:** Journal Article, Randomized Controlled Trial  |  **Topic area:** Cannabidiol  |  **CED Score:** 11 Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2 Why This Matters This study addresses a critical gap in understanding cannabis’s real-world anxiolytic efficacy by documenting daily symptom changes in self-medicating patients, enabling clinicians to provide evidence-based counseling on product selection and expected outcomes. The finding that flower and edible products produce differential anxiolytic effects has direct implications for treatment recommendations, as it suggests formulation type may be as clinically relevant as cannabinoid composition alone. These longitudinal data are essential for informing clinical guidelines on cannabis use in [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/), where current treatment decisions rely heavily on anecdotal evidence rather than systematic outcome measurement. **Quality Gate Alerts:** - Preclinical only **Abstract:** Research shows that delta-9-tetrahydrocannabinol (THC) is linked to increased anxiety, while cannabidiol (CBD) may have anxiolytic effects. Cannabis use is often driven by coping with anxiety, though its daily impact on anxiety remains unclear. This study examined daily associations between cannabis use and anxiety across 30 days in adults who wanted to use cannabis for [anxiety relief](https://cedclinic.com/cannabis-based-medicine-ptsd-anxiety-relief/). Participants (N = 345) used flower or edible products ad libitum and were randomly assigned to groups by product type (CBD, THC, or THC + CBD). Each day, participants reported cannabis use in the past 24 h and rated their anxiety. Linear mixed-effects models tested whether anxiety changed over time, differed by cannabinoid group, and varied with use. Anxiety significantly decreased over the study period in both flower and edibles groups. In the flower group, THC + CBD and [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%). In the edibles group, when participants used [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/), this was associated with a 24.9% reduction in anxiety over the 30 days. Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study. Clinical Perspective This study’s finding that edible cannabis products may produce more sustained anxiolytic effects than flower over 30 days is intriguing, yet several important limitations warrant cautious interpretation in clinical practice. The self-selected cohort of individuals motivated to use cannabis for anxiety introduces significant selection bias, and without biochemical confirmation of THC and CBD ratios across products, we cannot definitively attribute benefits to cannabinoid composition rather than user expectancy or unmeasured confounders like concurrent therapy or lifestyle changes. The ad libitum dosing protocol, while ecologically valid, obscures dose-response relationships and makes it difficult to identify optimal therapeutic windows or detect dose-dependent anxiety exacerbation, which THC can paradoxically produce in some individuals. For practitioners considering cannabis as an anxiety intervention, these results suggest that product formulation and delivery method may matter clinically, but emphasize the need for individualized titration, careful THC monitoring, structured follow-up, and concurrent evidence-based [anxiety treatment](https://cedclinic.com/benzodiazepine-discontinuation-rates-medical-cannabis/) rather than cannabis monotherapy.  |   |  CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) CED Clinic Blog[Smart Cannabis Dosing](https://cedclinic.com/smart-cannabis-dosing/) CED Clinic Blog[Cannabis Product Guide](https://cedclinic.com/cannabis-product-guide/) Further Reading Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[CBD and Liver Enzymes](https://cedclinic.com/cbd-liver-enzyme-elevation-study-jama-2025/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/41752306/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12941097/)[DOI ↗](https://doi.org/10.3390/ijerph23020224) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System Cannabis Anxiety Treatment Evidence](https://cedclinic.com/cbd-dominant-cannabis-anxiety-relief-study/) Explore evidence on how the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) mediates cannabis effects for [anxiety treatment](https://cedclinic.com/benzodiazepine-discontinuation-rates-medical-cannabis/). [Read More](https://cedclinic.com/cbd-dominant-cannabis-anxiety-relief-study/) [endocannabinoid system: Cannabis Anxiety Relief Study](https://cedclinic.com/endocannabinoid-system-cannabis-anxiety-relief/) Study findings on cannabis use and [anxiety relief](https://cedclinic.com/cannabis-based-medicine-ptsd-anxiety-relief/) through [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) modulation. [Learn More](https://cedclinic.com/endocannabinoid-system-cannabis-anxiety-relief/) [Cannabis Dosing in Family Medicine: Evidence-Based Care for Endocannabinoid System Regulation](https://cedclinic.com/cbd-dominant-edibles-anxiety-evidence-based-cannabis-dosing/) Guidance on cannabis dosing strategies for anxiety and endocannabinoid system regulation in clinical practice. [Explore Now](https://cedclinic.com/cbd-dominant-edibles-anxiety-evidence-based-cannabis-dosing/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoid%20Clinical%20Trials%3A%20Cannabis%20Use%20for%20Anxiety&url=https%3A%2F%2Fcedclinic.com%2Fcannabis-use-for-anxiety-clinical-trials-effects%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabis-use-for-anxiety-clinical-trials-effects%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoid%20Clinical%20Trials%3A%20Cannabis%20Use%20for%20Anxiety%20https%3A%2F%2Fcedclinic.com%2Fcannabis-use-for-anxiety-clinical-trials-effects%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).